Sichuan Kelun-Biotech Updates R&D Transaction Terms

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has provided additional details on their revised terms and pricing policies for the Auxiliary R&D Services Framework Agreement. The company’s internal procedures ensure that transactions for the purchase and sale of R&D equipment and materials are conducted at arm’s length, with prices benchmarked against book values and prevailing market rates, and overseen by their internal audit department. These measures are in place to guarantee fair market transactions within the Group and with the Remaining Kelun Group.

For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.